Reducing Neoplasia Recurrence After Endoscopic Resection of Large Colorectal Polyps (NCT06271941)
🩺 Plain-English Summary (8th-Grade Level)
Large (≥20mm) colorectal polyps often harbor areas of advanced neoplasia, making them immediate colorectal cancer (CRC) precursors. Such polyps have to be completely removed to prevent CRC and to avoid surgery and/or adjuvant therapy. The laterally spreading lesions (LSLs) are removed via endoscopic mucosal resection (EMR). However, recurrence is common. New techniques for LSL resection (hybrid argon plasma coagulation (h-APC) margin and base ablation) have shown a reduction in recurrence following the interventions. We hypothesize that performing hybrid argon plasma coagulation (h-APC) margin and base ablation during EMR of large (≥20mm) colorectal LSLs will lead to lower rates of lesion recurrence compared to Snare tip soft coagulation (STSC) margin ablation.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (3 items) and avoid the listed exclusions (9 items).
Location: Centre Hospitalier de l'Université de Montréal — Montreal, Quebec
Age range: 18 Years
🧪 Interventions in This Study
- Hybrid Argon Plasma Coagulation (h-APC) (PROCEDURE)
- Snare tip soft coagulation (STSC) (PROCEDURE)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- inflammatory bowel disease;
- non-elective colonoscopy;
- poor general health (American Society of Anesthesiologists classification \>III);
- coagulopathy or thrombocytopenia (international normalized ratio ≥1.5 or platelets \<50 x 109/L);
- pedunculated polyps (Paris class Ip, Isp);
- overt signs of deep submucosal invasive cancer (JNET 3);
- biopsy proven invasive carcinoma in a potential study polyp.
- Pregnant women
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (1 Sites)
- Centre Hospitalier de l'Université de Montréal — Montreal, Quebec
📞 Contact the Study Coordinator
Phone: (514) 890-8000
Email: julie.fleury.chum@ssss.gouv.qc.ca
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Colorectal Cancer
- Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples From Colorectal Cancer Patients — Nashville, Tennessee
- Histotripsy Plus Chemotherapy vs Chemotherapy Alone for Advanced Colorectal Liver Metastasis — Cleveland, Ohio
- Reducing Metabolic Dysregulation in Dyads — Columbia, South Carolina
- Impact of Colorectal Cancer and Nutrition Education Program Among Minority Patients With Type 2 Diabetes — Los Angeles, California
- Changes in Reproductive and Sexual Health in People With Early Onset Colorectal Cancer — Basking Ridge, New Jersey
Explore by condition: All Colorectal Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.